Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT04402385 · ClinicalTrials.gov registry record · Phase 2
Aspirin to Prevent Preeclampsia in Women With Elevated Blood Pressure and Stage 1 Hypertension (ASPPIRE)
A Phase 2 study, sponsored by Yale University.
- Terminated
- Registry status
- Phase 2
- Development phase
- 50
- Enrollment target
NCT04402385 is a Phase 2 study that was terminated before completion, run by Yale University. The registered enrollment target is 50 participants.
The verdict
NCT04402385, a Phase 2 study, was terminated before completion, sponsored by Yale University.
- TERMINATED
- Registry status
- Phase 2
- Development phase
- 50 participants
- Enrollment target
Study Summary
To determine if low dose aspirin reduces the incidence of hypertensive disorders of pregnancy (gestational hypertension, preeclampsia, eclampsia, and HELLP syndrome) in pregnant women with stage 1 hypertension and elevated blood pressure.
Interventions
- DRUG Placebo
- DRUG Aspirin 81 mg
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 50 participants |
| Start Date | 2020-08-06 |
| Est. Completion | 2022-06-22 |
| Phase | Phase 2 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT04402385
The ClinicalTrials.gov registry entry for NCT04402385 describes a study currently listed as terminated, categorized as Phase 2. The registered enrollment target is 50 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Yale University, which has 1,492 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 2 interventions - of which Placebo is the first listed.
NCT04402385 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT04402385 about?
NCT04402385 is a clinical study titled "Aspirin to Prevent Preeclampsia in Women With Elevated Blood Pressure and Stage 1 Hypertension (ASPPIRE)". To determine if low dose aspirin reduces the incidence of hypertensive disorders of pregnancy (gestational hypertension, preeclampsia, eclampsia, and HELLP syndrome) in pregnant women with stage 1 hypertension and elevated blood pressure.
What is the current status of trial NCT04402385?
This trial is currently terminated. It is a Phase 2 study. The enrollment target is 50 participants. The study started on 2020-08-06. Estimated completion is 2022-06-22.
What interventions are being tested in trial NCT04402385?
The interventions under investigation include: Placebo (DRUG), Aspirin 81 mg (DRUG).
Who is sponsoring clinical trial NCT04402385?
This trial is sponsored by Yale University, which has 1,492 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.